Quantcast
Last updated on April 17, 2014 at 15:21 EDT

Latest Pharmos Corporation Stories

2012-07-30 02:25:52

ISELIN, N.J., July 30, 2012 /PRNewswire/ -- Pharmos Corporation (OTCQB: PARS) today reported financial results for the second quarter and six-month period ended June 30, 2012. These results are included in the Company's Quarterly Report on Form 10-Q which has been filed with the SEC. In May the Company issued a press release announcing the successful completion of a proof-of concept trial of levotofisopam for the treatment of gout. The trial was open label and 100% of the subjects were...

2012-05-17 10:26:02

ISELIN, N.J., May 17, 2012 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) today announced that it has successfully completed a proof-of-concept clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout. This phase 2a trial was conducted at the Duke Clinical Research Unit of Duke University and the principal investigator was John Sundy, MD, PhD, an expert and key opinion leader in the treatment of gout. The trial was designed to assess...

2012-04-16 02:28:45

ISELIN, N.J., April 16, 2012 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) today reported financial results for the first quarter ended March 31, 2012. The Company recorded a net loss of $0.6 million, or $(0.01) per share, for the first quarter 2012 compared to a net loss of $0.6 million, or $(0.01) per share, in the first quarter 2011. The Company is currently conducting a clinical trial at the Duke Clinical Research Unit to evaluate levotofisopam as a treatment for gout. As of...

2012-04-05 10:24:46

ISELIN, N.J., April 5, 2012 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) today provided an update on the ongoing clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout. This phase 2a proof-of-concept trial is being conducted at the Duke Clinical Research Unit of Duke University and the principal investigator is John Sundy, MD, PhD an expert in the treatment of gout. The trial is designed to assess the safety and efficacy of...

2012-02-17 15:34:00

ISELIN, N.J., Feb. 17, 2012 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) today reported financial results for the fourth quarter and twelve-month period ended December 31, 2011. These results are included in the Company's Yearly Report on Form 10-K which has been filed with the SEC. Fourth Quarter Ended December 31, 2011 The Company recorded a net loss of $0.4 million, or $0.01 per share, for the fourth quarter 2011 compared to a net loss of $0.2 million, or $0.00 per share, in the...

2012-01-10 15:15:00

ISELIN, N.J., Jan. 10, 2012 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) announced today the dosing of the first patients in the US using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout. This phase 2a proof-of-concept trial is being conducted at the Duke Clinical Research Unit of Duke University and the principal investigator is John Sundy, MD, PhD an expert in the treatment of gout. The trial is designed to assess the safety and...

2011-10-31 15:15:00

ISELIN, N.J., Oct. 31, 2011 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) today reported financial results for the third quarter and nine-month period ended September 30, 2011. These results are included in the Company's Quarterly Report on Form 10-Q which has been filed with the SEC. Third Quarter Ended September 30, 2011 The Company recorded a net loss of $0.4 million, or $0.01 per share, for the third quarter 2011 compared to a net loss of $0.5 million, or $0.01 per share, in the...

2011-08-08 15:15:00

ISELIN, N.J., Aug. 8, 2011 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) today reported financial results for the second quarter and six-month period ended June 30, 2011. These results are included in the Company's Quarterly Report on Form 10-Q which has been filed with the SEC. Second Quarter Ended June 30, 2011 The Company recorded a net loss of $0.5 million, or $0.01 per share, for the second quarter 2011 compared to a net loss of $0.4 million, or $0.01 per share, in the second...

2011-04-28 15:15:00

ISELIN, N.J., April 28, 2011 /PRNewswire/ -- Pharmos Corporation (Pink Sheets: PARS) today reported financial results for the first quarter ended March 31, 2011. The Company recorded a net loss of $0.6 million, or $0.01 per share, for the first quarter 2011 compared to a net loss of $0.5 million, or $0.01 per share, in the first quarter 2010. Research & development expenses for the first quarter increased by $158,788 or 129% from $122,995 in 2010 to $281,783 in 2011. The primary...

2011-02-17 15:15:00

ISELIN, N.J., Feb. 17, 2011 /PRNewswire/ -- Pharmos Corporation (Pink Sheets: PARS) today reported financial results for the fourth quarter and twelve-month period ended December 31, 2010. These results are included in the Company's Yearly Report on Form 10-K which has been filed with the SEC. Fourth Quarter Ended December 31, 2010 The Company recorded a net loss of $152,000, or $0.00 per share, for the fourth quarter 2010 compared to a net income of $4,292,000, or $0.07 per share, in the...